Senti Bio to Participate in Upcoming Investor Conferences
03. September 2024 08:15 ET
|
Senti Biosciences, Inc.
Senti Bio will participate in two upcoming investor conferences in September.
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
13. August 2024 16:05 ET
|
Senti Biosciences, Inc.
– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM...
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
13. Mai 2024 08:15 ET
|
Senti Biosciences, Inc.
Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
09. Mai 2024 16:05 ET
|
Senti Biosciences, Inc.
Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
30. April 2024 08:05 ET
|
Senti Biosciences, Inc.
Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
21. März 2024 16:05 ET
|
Senti Biosciences, Inc.
– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated...